• 1
    Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med. 1993; 328: 10021006.
  • 2
    Velasquez WS, Cabanillas F, Salvador P, et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood. 1988; 71: 117122.
  • 3
    Velasquez WS, McLaughlin P, Tucker S, et al. ESHAP — an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol. 1994; 12: 11691176.
  • 4
    Cabanillas F. Experience with ifosfamide combinations in malignant lymphomas. Semin Oncol. 1989; 16(1 Suppl 3 ): 7881.
  • 5
    Rodriguez MA, Cabanillas FC, Hagemeister FB, et al. A phase II trial of mesna/ifosfamide, mitoxantrone and etoposide for refractory lymphomas. Ann Oncol. 1995; 6: 609611.
  • 6
    Moskowitz CH, Bertino JR, Glassman JR, et al. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. J Clin Oncol. 1999; 17: 37763785.
  • 7
    Hickish T, Roldan A, Cunningham D, et al. EPIC: an effective low toxicity regimen for relapsing lymphoma. Br J Cancer. 1993; 68: 599604.
  • 8
    Palmieri G, Lauria R, Caponigro F, et al. Salvage chemotherapy for non Hodgkin's lymphoma of unfavourable histology with a combination of CCNU and vinblastine. Hematol Oncol. 1990; 8: 179183.
  • 9
    Ruit JB, Lowenberg B, Hagenbeek A, et al. Phase II study of lomustine, cytarabine, mitoxantrone, and prednisone (CAMP) combination chemotherapy for doxorubicin-resistant intermediate- and high-grade malignant non-Hodgkin's lymphoma. Semin Oncol. 1990; 17: 2427.
  • 10
    Dorigo A, Mansberg R, Kwan YL. Lomustine, etoposide, methotrexate and prednisone (LEMP) therapy for relapsed and refractory non-Hodgkin's lymphoma. Eur J Haematol. 1993; 50: 3740.
  • 11
    Papadopoulou MV, Epperly MW, Mainwarning A, et al. Potentiation of antineoplastic drugs in vitro and in vivo by DNA-intercalating bioreductive agents[abstract]. Proc Am Assoc Cancer Res. 1992; 33: 2619.
  • 12
    Durand J. Cisplatin and CCNU synergism in spheroid cell subpopulation. Br J Cancer. 1990; 62: 947953.
  • 13
    Koldamova RP, Lefterov IM. Synergistic effect of CCNU and bleomycin on human lymphocytes exposed at late G1 and G2 states of the cell cycle. Mutat Res. 1991; 260: 265269.
  • 14
    Dincol D, Icli F, Karaoguz H, et al. Mesna/ifosfamide, mitoxantrone, etoposide, bleomycin, vincristine, prednisone (MINE-BOP) combination chemotherapy in the treatment of refractory and relapsed non-Hodgkin's lymphoma. Acta Oncol. 1995; 34: 937940.
  • 15
    Hoogstraten B, Haas CD, Haut A, Talley RW, Rivkin S, Isaacs BL. CCNU and bleomycin in the treatment of cancer: a Southwest Oncology Group study. Med Pediatr Oncol. 1975; 1: 95106.
  • 16
    Cohen SM, Ohnuma T, Ambinder EP, Holland JF. Lomustine, bleomycin, and cisplatin in patients with metastatic malignant melanoma. Cancer Treat Rep. 1986; 70: 688689.
  • 17
    Harris NL, Jaffe ES, Diebald J, et al. The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues: report of the clinical advisory committee meeting-Airlie House, Virginia, November, 1997. J Clin Oncol. 1999; 17: 38353849.
  • 18
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457481.
  • 19
    Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966; 50: 163170.
  • 20
    Cox DR. Regression models and life tables. J R Stat Soc. 1972; 34: 187220.
  • 21
    Cabanillas F, Hageimeister FB, McLaughlin P, et al. MIME combination chemotherapy for refractory or recurrent lymphomas. J Clin Oncol. 1987; 5: 407412.
  • 22
    Freeman DH. Applied categorical data analysis. New York: Marcel Dekker, Inc., 1987.
  • 23
    Rodriguez MA, Cabanillas FC, Velasquez W, et al. Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP. J Clin Oncol. 1995; 13: 17341741.
  • 24
    Haim N, Ben-Shahar M, Faraggi D, Tsuri-Etzioni A, Levion M, Epelbaum R. Dexamethasone, etoposide, ifosfamide, and cisplatin as second-line therapy in patients with aggressive non-Hodgkin's lymphoma. Cancer. 1997; 80: 19891996.
  • 25
    Armitage JO, Vose JM, Bierman PJ. Salvage therapy for patients with non-Hodgkin's lymphoma. Monogr Natl Cancer Inst. 1990; 10: 3943.
  • 26
    Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med. 1995; 333: 15401545.
  • 27
    Blay J, Gomez F, Sebban C, et al. The international prognostic index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group. Blood. 1998; 92: 35623568.
  • 28
    Josting A, Reiser M, Rueffer U, Salzberger B, Diehl V, Engert A. Treatment of primary progressive Hodgkin's and aggressive non-Hodgkin's lymphoma: is there a chance of cure? J Clin Oncol. 2000; 18: 332339.
  • 29
    Kewalramani T, Zelenetz AD, Hedrick EE, et al. High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin's lymphoma: an intention-to-treat analysis. Blood. 2000; 96: 23992404.
  • 30
    Villela L, Lopez-Guillermo A, Montoto S, et al. Prognostic features and outcome in patients with diffuse large B-cell lymphoma who do not achieve a complete response to first-line regimens. Cancer. 2001; 91: 15571562.
  • 31
    Vose JM, Zhang MJ, Rowlings PA, et al. Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol. 2001; 19: 406413.
  • 32
    Philip T, Armitage JO, Spitzer G, et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high grade non-Hodgkin's lymphoma. N Engl J Med. 1987; 316: 14931498.
  • 33
    Nückel H, Dürig J, Dührsen U. Salvage chemotherapy according to the ASHAP protocol: a single-center study of 24 patients with relapsed or refractory aggressive non-Hodgkin's lymphomas. Ann Hematol. 2003; 82: 481486.
  • 34
    Jagannath S, Velasquez WS, Tucker SL, et al. Tumor burden assessment and its implication for a prognostic model in advanced diffuse large-cell lymphoma. J Clin Oncol. 1986; 4: 859865.
  • 35
    Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002; 346: 235242.